Scale for the assessment and rating of ataxia -: Development of a new clinical scale
Scale for the assessment and rating of ataxia -: Development of a new clinical scale
复制标题
DOI：
10.1212/01.wnl.0000219042.60538.92
复制
发表时间：
2006-06-13
期刊：
影响因子：
9.9
通讯作者：
Klockgether, T.
中科院分区：
文献类型：
--
作者：
Schmitz-Huebsch, T.;du Montcel, S. Tezenas;Klockgether, T.
目的：建立一套可靠、有效的共济失调严重程度临床评定量表。方法：作者设计了共济失调评定量表(SARA)，并对167例和119例脊髓小脑性共济失调患者进行了测试。结果：患者应用SARA的平均时间为14.2±7.5分钟(5~40分钟)。评定者间信度较高，组内系数(ICC)为0.98。重测信度较高，ICC为0.90。内部一致性很高，Cronbach‘s Alpha为0.94。析因分析表明，评级结果由单一因素决定。SARA评级与使用视觉模拟量表的全球评估呈线性关系，表明该量表具有线性(p<；0.0001，r(2)=0.98.SARA评分随着疾病分期的增加而增加(p<；0.001)，与Barthel指数(r=-0.80，p<；0.001)和亨廷顿病统一评定量表(UHDRS-IV)的第IV部分(功能评定)(r=-0.89，p<；0.0001)密切相关，而与病程(r=0.34，p<；0.0002)结论：共济失调评定量表是一种可靠有效的共济失调测量工具，可作为临床试验的主要结果测量工具。
Objective: To develop a reliable and valid clinical scale measuring the severity of ataxia. Methods: The authors devised the Scale for the Assessment and Rating of Ataxia ( SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia. Results: The mean time to administer SARA in patients was 14.2 +/- 7.5 minutes ( range 5 to 40). Interrater reliability was high, with an intraclass coefficient ( ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's alpha of 0.94. Factorial analysis revealed that the rating results were determined by a single factor. SARA ratings showed a linear relation to global assessments using a visual analogue scale, suggesting linearity of the scale ( p < 0.0001, r(2) = 0.98). SARA score increased with the disease stage ( p < 0.001) and was closely correlated with the Barthel Index ( r = - 0.80, p < 0.001) and part IV ( functional assessment) of the Unified Huntington's Disease Rating Scale ( UHDRS-IV) ( r = - 0.89, p < 0.0001), whereas it had only a weak correlation with disease duration ( r = 0.34, p < 0.0002) Conclusions: The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.